| Metric | Value (₹ Cr) | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue | 13.21 | 40.1% | 27.3% |
| Total Income | 13.81 | 38.2% | 25.8% |
| Expenditure | 12.61 | 32.4% | 21.0% |
| PBT | 1.20 | 67.5% | 54.7% |
| Net Profit | 0.55 | 80.2% | 74.9% |
| OPM | 11.94% | 5.46pp | 2.42pp |
| NPM | 3.97% | 8.45pp | 7.78pp |
| EPS | 0.49 | 77.8% | 73.4% |
Sanjivani Paranteral FY26: EBITDA at ₹114 mn, PAT at ₹66.94 mn
15 May 2026 · 15 May, 4:16 pm
Summary
Sanjivani Paranteral Limited announced its audited financial results for the fourth quarter and full financial year ended March 31, 2026, reporting a total income of ₹697.56 mn for FY26 and ₹138.09 mn for Q4 FY26. The company achieved an EBITDA of ₹114.00 mn for FY26, with a margin of 16.34%, and a PAT of ₹66.94 mn, representing a 9.60% margin. A key highlight for the year was the commencement of commercial production at its new IV Fluid Infusion Plant in Pune, significantly strengthening its manufacturing capabilities and expanding its product portfolio. Mr. Ashwani Khemka, Chairman & Managing Director, highlighted the year as one of "steady operational progress and focused execution," positioning the company for "scalable and sustainable long-term growth" into FY27.
Key Highlights
- 1
Sanjivani Paranteral Limited reported a full-year FY26 total income of ₹697.56 mn.
- 2
For FY26, EBITDA stood at ₹114.00 mn, achieving an EBITDA margin of 16.34%, while Profit after Tax (PAT) was ₹66.94 mn with a PAT margin of 9.60%.
- 3
In Q4 FY26, the company recorded a total income of ₹138.09 mn and a PAT of ₹5.48 mn.
- 4
The Tablets segment demonstrated robust growth, with revenue increasing by approximately 7.5% YoY to ₹279.14 mn for FY26 and by approximately 11.1% YoY to ₹54.60 mn in Q4 FY26.
- 5
Exports were a significant contributor to revenue, accounting for 78.50% of revenue from operations in FY26, totaling ₹508 mn.
- 6
A major business milestone was achieved with the commencement of commercial production at the newly established IV Fluid Infusion Plant in Pune, enhancing manufacturing capabilities.
- 7
The new facility is expected to improve operational efficiency, enhance product quality, and support growing demand across domestic and export markets.
Management Comments
Ashwani Khemka
FY26 has been a year of steady operational progress and focused execution for Sanjivani Paranteral Limited. The commencement of commercial production at our newly established IV Fluid Infusion Plant in Pune marks a significant milestone in strengthening our manufacturing capabilities and expanding our healthcare product portfolio. Equipped with advanced technology and sustainable infrastructure, the facility is expected to improve operational efficiency, enhance product quality, and support growing demand across domestic and export markets. Our continued focus on quality manufacturing, disciplined cost management, and long-term customer relationships has enabled us to maintain stable business performance in a dynamic operating environment. This expansion further strengthens our market presence and positions the Company for scalable and sustainable long-term growth as we move into FY27. We remain committed to evaluating new growth opportunities and strategic initiatives aimed at enhancing operational scale and creating long-term value for all stakeholders.
Informational and educational content only. Not investment advice.